Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8WTW4

UPID:
NPRL2_HUMAN

ALTERNATIVE NAMES:
Gene 21 protein; Nitrogen permease regulator 2-like protein; Tumor suppressor candidate 4

ALTERNATIVE UPACC:
Q8WTW4; A8K831; Q6FGS2; Q9Y249; Q9Y497

BACKGROUND:
GATOR1 complex protein NPRL2, with alternative names such as Gene 21 protein and Tumor suppressor candidate 4, is integral to the amino acid-sensing branch of the mTORC1 pathway. By mediating the GATOR1 complex's GAP activity, NPRL2 plays a critical role in cellular amino acid response, impacting cell growth and metabolism.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of NPRL2 could open doors to potential therapeutic strategies. Its direct association with familial focal epilepsy and its tumor suppressor functions make it a promising candidate for the development of novel therapeutic approaches for epilepsy and cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.